Adriana Valentini1, Amy Finch, Jan Lubinski, Tomasz Byrski, Parviz Ghadirian, Charmaine Kim-Sing, Henry T Lynch, Peter J Ainsworth, Susan L Neuhausen, Ellen Greenblatt, Christian Singer, Ping Sun, Steven A Narod. 1. Adriana Valentini, Amy Finch, Ping Sun, and Steven A. Narod, Women's College Research Institute; Ellen Greenblatt, Centre for Fertility and Reproductive Health, Mount Sinai Hospital, University of Toronto, Toronto; Peter J. Ainsworth, London Regional Cancer Program, London, Ontario; Parviz Ghadirian, Research Center of the University of Montreal Hospital Centre, Montreal, Quebec; Charmaine Kim-Sing, BC Cancer Agency, Vancouver, British Columbia, Canada; Henry T. Lynch, Creighton University School of Medicine, Omaha, NE; Susan L. Neuhausen, Beckman Research Institute, City of Hope, Duarte, CA; Jan Lubiński and Tomasz Byrski, Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland; and Christian Singer, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
Abstract
PURPOSE: To determine the likelihood of long-term amenorrhea after treatment with chemotherapy in women with breast cancer who carry a BRCA1 or BRCA2 mutation. PATIENTS AND METHODS: We conducted a multicenter survey of 1,954 young women with a BRCA1 or BRCA2 mutation who were treated for breast cancer. We included premenopausal women who were diagnosed with invasive breast cancer between 26 and 47 years of age. We determined the age of onset of amenorrhea after breast cancer for women who were and were not treated with chemotherapy, alone or with tamoxifen. We considered chemotherapy-induced amenorrhea to have occurred when the patient experienced ≥ 2 years of amenorrhea, commencing within 2 years of initiating chemotherapy, with no resumption of menses. RESULTS: Of the 1,426 women who received chemotherapy, 35% experienced long-term amenorrhea. Of the 528 women who did not receive chemotherapy, 5.3% developed long-term amenorrhea. The probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed before age 30 years, 33% for women age 31 to 44 years, and 79% for women diagnosed after age 45 years (P trend < .001). The probability of induced amenorrhea was higher for women who received tamoxifen than for those who did not (52% v 29%; P < .001). CONCLUSION: Age at treatment and use of tamoxifen are important predictors of chemotherapy-induced amenorrhea in women who carry a BRCA1 or BRCA2 mutation. The risk of induced long-term amenorrhea does not seem to be greater among mutation carriers than among women who do not carry a mutation.
PURPOSE: To determine the likelihood of long-term amenorrhea after treatment with chemotherapy in women with breast cancer who carry a BRCA1 or BRCA2 mutation. PATIENTS AND METHODS: We conducted a multicenter survey of 1,954 young women with a BRCA1 or BRCA2 mutation who were treated for breast cancer. We included premenopausal women who were diagnosed with invasive breast cancer between 26 and 47 years of age. We determined the age of onset of amenorrhea after breast cancer for women who were and were not treated with chemotherapy, alone or with tamoxifen. We considered chemotherapy-induced amenorrhea to have occurred when the patient experienced ≥ 2 years of amenorrhea, commencing within 2 years of initiating chemotherapy, with no resumption of menses. RESULTS: Of the 1,426 women who received chemotherapy, 35% experienced long-term amenorrhea. Of the 528 women who did not receive chemotherapy, 5.3% developed long-term amenorrhea. The probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed before age 30 years, 33% for women age 31 to 44 years, and 79% for women diagnosed after age 45 years (P trend < .001). The probability of induced amenorrhea was higher for women who received tamoxifen than for those who did not (52% v 29%; P < .001). CONCLUSION: Age at treatment and use of tamoxifen are important predictors of chemotherapy-induced amenorrhea in women who carry a BRCA1 or BRCA2 mutation. The risk of induced long-term amenorrhea does not seem to be greater among mutation carriers than among women who do not carry a mutation.
Authors: Ian E Smith; Mitch Dowsett; Yoon-Sim Yap; Geraldine Walsh; Per E Lønning; Richard J Santen; Daniel Hayes Journal: J Clin Oncol Date: 2006-06-01 Impact factor: 44.544
Authors: Jeanne A Petrek; Michelle J Naughton; L Douglas Case; Electra D Paskett; Elizabeth Z Naftalis; S Eva Singletary; Paniti Sukumvanich Journal: J Clin Oncol Date: 2006-02-13 Impact factor: 44.544
Authors: Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Bohdan Górski; Pawel Domagala; Cezary Cybulski; Oleg Oszurek; Marek Szwiec; Karol Gugala; Malgorzata Stawicka; Zbigniew Morawiec; Tomasz Mierzwa; Hanna Janiszewska; Ewa Kilar; Elzbieta Marczyk; Beata Kozak-Klonowska; Monika Siolek; Dariusz Surdyka; Rafal Wisniowski; Michal Posmyk; Ping Sun; Jan Lubinski; Steven A Narod Journal: J Clin Oncol Date: 2013-08-12 Impact factor: 44.544
Authors: Benjamin T Allaire; Donatus U Ekwueme; Gery P Guy; Chunyu Li; Florence K Tangka; Katrina F Trivers; Susan A Sabatino; Juan L Rodriguez; Justin G Trogdon Journal: Am J Prev Med Date: 2016-02 Impact factor: 5.043
Authors: Valentino Martelli; Maria Maddalena Latocca; Tommaso Ruelle; Marta Perachino; Luca Arecco; Kristi Beshiri; Maria Grazia Razeti; Marco Tagliamento; Maurizio Cosso; Piero Fregatti; Matteo Lambertini Journal: Breast Cancer (Dove Med Press) Date: 2021-05-24